The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals and ...

Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment ...

“Previously, if a CMS student missed 11 or more class periods, did not make up missed time or have a medical waiver, he or ...

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of ...

After both insurers challenged the agency in court, the CMS improved scores for 12 UnitedHealth contracts and seven Centene contracts.

“Cell and gene therapies hold significant potential to improve patient outcomes and transform lives, ultimately reducing long ...

The Centers for Medicare & Medicaid Services Nov. 22 released an FAQ on special enrollment periods resulting from significant ...

Bharatiya Janata Party (BJP) leader Devendra Fadnavis will take oath as the Chief Minister of Maharashtra on Thursday in ...

Effective enforcement of the Hospital Price Transparency Rule can empower patients, foster competition, and help control ...

CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.

The federal Centers for Medicare and Medicaid Services (CMS) issued QSO-25-09-ALL on November 21, 2024, revising Core Appendix Q guidance to the ...